The utility of NELL-1 as a biomarker for cancer screening in MN requires further study [50,[69], [70], [71]] For cancer screening in other types of glomerular disease, further development in biomarkers {proteins, auto-antibodies, nucleic acids (cell-free DNA and RNA) in serum or other bodily fluids}, with a high degree of sensitivity and specificity are required. This evidence concerns the gene NELL1 and cancer.